Pierre Beauparlant has more than 19 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization. As Chief Executive Officer, Dr. Beauparlant is responsible for the direction and execution of business strategy for PreciThera.
Dr. Beauparlant most recently served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities.
Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property. Dr. Beauparlant is also Chief Business Officer at Therillia.
Dr. Beauparlant holds a Ph.D. from McGill University.
Philippe Crine has over 30 years experience in protein engineering and molecular endocrinology.
As cofounder and chief scientific officer of Enobia Pharma, Dr. Crine was responsible for development of new tharapies for rare bone metabolic diseases. Notably, Dr. Crine was responsible for the initiation and preclinical development of the asfotase alfa (now Strensiq®) prior to Enobia’s acquisition by Alexion. In 2015 Strensiq received worldwide marketing approval for hypophosphatasia, an ultra-rare metabolic bone disease.
Both prior to and simultaneously with the creation of Enobia, Dr. Crine also served as full professor at the Université de Montréal Medical School, chair of the Biochemistry department and finally assistant dean for Medical Research. Under his tenure the Biochemistry department recruited four new faculty and created a structural biology group jointly with McGill University and the National Research Council of Canada.
Dr. Crine received his Ph.D from the Université de Montréal Medical School and postdoctoral training at Brandeis University (Massachusetts) and at the Clinical Research Institute of Montreal. He co-authored over 120 publications in peer reviewed scientific journals.
Michael Dixon, has over 18 years’ experience working in an executive role for venture-backed companies.
Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada.
Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr. Dixon is also president and chief executive officer at Therillia Development Company.
Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.